ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CHE / insiders
HIMS (60) LFST (67) OPCH (74) BTSG (67) ⌘ Pro Terminal →

Chemed Corp (CHE) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$534.72 -1.33% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $534.72

Chemed Corp (CHE) earns a Roarable Rating of A- (Buy) with 83/100 RQD Confidence. High-quality cash engine (32.5% gross margin, 23% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE A- • BUY Cap $6.96B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CHE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CHE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Chemed Corp (NYSE: CHE) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 83/100 at a spot price of $534.72 (-1.33% 1D, market cap $6.96B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 16/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, CHE ranks #11 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CHE compare to HIMS and LFST in the Health Care sector?
▼

Within the Health Care sector (Medical/Nursing Services), CHE carries a Roarable A- (83/100 RQD), trailing P/E of N/A, gross margin of 32.5%, and ROIC of 23.4%. By comparison, HIMS (Hims & Hers Health Inc.) holds a C- grade (60/100 RQD, P/E 53.9x, ROIC 8.4%, cap $6.46B) and LFST (LifeStance Health Group Inc.) posts a C+ grade (67/100 RQD, P/E N/A, ROIC 1.2%, cap $5.12B). Among the 5-stock peer group, OPCH leads on earnings multiple (23.0x) while CHE leads on capital efficiency (23.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CHE?
▼

Per CHE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000019584), Chemed Corp generated $2.53B in revenue (+65.3% YoY), $265.2K in net income, and $325.5M in free cash flow against $1.54B in total assets and $251.5M in total debt. Key quantitative strengths: Strong cash generator (32.5% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $534.72 (+0.00%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 12.9% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 83/100 (A-) historically ranked in the Top 7% of excess returns over the next 90 days (+8.7% avg 90D alpha vs SPY • 72.2% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • A-
025507510083
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw A- · Rk A-
Cash (17)Whales (16)SEC (18)Macro (16)CEO (16)
Each axis scored 0–20
12M PRICE TARGET CONE+11.3% Base Target
$702 Bull$595 Base$438 Bear
📬 FREE CHE RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CHE)Realized 20D OHLCV Swing Band: ±4.9%
Deterministic 5-Pillar Attribution (83/100 Composite)
🔍 WHY CHE SCORES 83/100 (A-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (22% of score)

Altman Z-Score 12.68 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+17/20 pts (20% of score)

SEC XBRL FY 2025 (10-K): 12.9% FCF Margin ($325.5M FCF) & 32.5% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution16/20 pts (-4 pt drag)

Cannibal Buyback (-2.36% YoY Shares) & executive Form 4 sales trim 4 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
75
Grade B+$513.18-0.4% Next Q
Q2 (-2Q)
78
Grade A-$511.37+4.3% Next Q
Q3 (-1Q)
80
Grade A-$533.36+0.3% Next Q
Current
83
Grade A-$534.72+8.7% Hist 90D α
Trajectory: B+ (75) → A- (83)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the CHE Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 83/100 (A-) score, CHE faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 30.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($514.59) or 200D SMA ($464.05) invalidates the momentum regime and cuts Target Base ($594.88) toward Bear Floor ($438.47).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CHE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CHE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 83%NO 17%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

CHE Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (CHE)

No recent open-market Form 4 cluster sales or emergency dumps flagged on CHE. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (CHE Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CHE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +25.54%▲ ASCENDING TRIANGLE
2026-11-03O $541.9H $541.9L $534.7C $534.7VOL 180.5K
RES: $562.7SUP: $499.7SMA50: $514.6SMA200: $464.1
$573.9$525.8$477.7$429.6$381.5RES $562.7SUP $499.7$534.72026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CHE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CHE Butterfly Map → + Track CHE →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
16.9%/yr Implied 5Y Growth

vs. +65.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CHE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CHE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CHE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CHE)

Health Care Rank #11 of 1015 ⚔️ HIMS vs CHE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CHE vs. HIMS, LFST, OPCH, BTSG)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Chemed Corp (CHE) ranks #11 by composite RQD confidence (83/100, grade A-) and #134 by equity capitalization ($6.96B). Within this direct 5-issuer industry benchmark cohort, OPCH leads on earnings valuation at 23.0x trailing P/E, while CHE leads on capital efficiency and profitability with 23.4% ROIC and 32.5% gross margin. CHE currently leads its immediate peer cohort in composite quantitative strength at 83/100 (A-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CHE ACTIVE
Chemed Corp
A- 83/100 — 32.5% 23.4% -1.33% $6.96B Benchmark Subject
HIMS
Hims & Hers Health Inc.
C- 60/100 53.9x 73.8% 8.4% -6.71% $6.46B /hims-vs-che →
LFST
LifeStance Health Group Inc.
C+ 67/100 — — 1.2% -1.72% $5.12B /lfst-vs-che →
OPCH
Option Care Health Inc.
B 74/100 23.0x 19.3% 11.9% -0.06% $4.77B /opch-vs-che →
BTSG
BrightSpring Health Services Inc.
C+ 67/100 63.0x 11.8% 5.5% +11.08% $13.24B /btsg-vs-che →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000019584 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Chemed Corp (CHE) reported GAAP revenue of $2.53B (+65.3% vs. FY2024 revenue of $1.53B , and +92.4% cumulative change since FY2023) , GAAP net income of $265.2K, operating cash flow of $388.3M, and free cash flow of $325.5M (-11.5% YoY). On the balance sheet, CHE closed FY2025 with $1.54B in total assets against $251.5M in total debt (Altman Z-Score: 12.68, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $2.53B $265.2K $388.3M $325.5M $1.54B $251.5M
FY2024 (FY) 2024-12-31 $1.53B $302.0K $417.5M $368.0M $1.67B $247.3M
FY2023 (FY) 2023-12-31 $1.32B $272.5K $330.3M $271.1M $3.90B $911.6M

3. CHE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CHE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Chemed Corp (NYSE: CHE) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 83/100 at a spot price of $534.72 (-1.33% 1D, market cap $6.96B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 16/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, CHE ranks #11 in composite RQD confidence.

How does CHE compare to HIMS and LFST in the Health Care sector?

Within the Health Care sector (Medical/Nursing Services), CHE carries a Roarable A- (83/100 RQD), trailing P/E of N/A, gross margin of 32.5%, and ROIC of 23.4%. By comparison, HIMS (Hims & Hers Health Inc.) holds a C- grade (60/100 RQD, P/E 53.9x, ROIC 8.4%, cap $6.46B) and LFST (LifeStance Health Group Inc.) posts a C+ grade (67/100 RQD, P/E N/A, ROIC 1.2%, cap $5.12B). Among the 5-stock peer group, OPCH leads on earnings multiple (23.0x) while CHE leads on capital efficiency (23.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CHE?

Per CHE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000019584), Chemed Corp generated $2.53B in revenue (+65.3% YoY), $265.2K in net income, and $325.5M in free cash flow against $1.54B in total assets and $251.5M in total debt. Key quantitative strengths: Strong cash generator (32.5% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CHE trading relative to its 50-day, 200-day, and 52-week technical levels?

CHE last traded at $534.72 (-1.33% on volume of 180,536 shares), positioning the stock +3.91% above its 50-day simple moving average ($514.59) and +15.23% above its 200-day simple moving average ($464.05). Across its 52-week range of $365.21 to $562.24, CHE sits at the 86.0% percentile with a 14-day RSI of 59.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±4.9% ($508.52 to $560.92).

Direct Sub-Reports: CHE RQD Cockpit CHE 12M Forecast CHE Earnings & Move CHE Dividends & DRIP CHE Insiders & 13F CHE Whale Options CHE Profit Sankey CHE News & Why
ROARABLE RATING BRIEF • RQD 83/100 (A-) ✓ SEC XBRL & RQD VERIFIED

CHE — Chemed Corp: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Chemed Corp (CHE) earns a live Roarable RQD composite score of 83/100, corresponding to a A- letter grade (Roarable Buy) at a spot price of $534.72 (-1.33% 1D, market capitalization $6.96B).

  • Fundamental Cash Engine (17/20): Anchored by return on invested capital (ROIC) of 23.4%, gross margin of 32.5%, operating margin of 13.4%, and free cash flow yield of 4.60%.
  • Whale 13F & Options Flow (16/20) + Insider Conviction (16/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (16/20) + Forensic Balance Sheet (18/20): Incorporates a 1.08x equity beta, Altman Z-Score of 12.68, Piotroski F-Score of 7/9, and Debt/Equity of 0.24x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Chemed Corp (CHE) is a NYSE-listed issuer in the Health Care sector, operating in the Medical/Nursing Services industry. — The company carries a market capitalization of $7.1B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Chemed Corp (CHE) reported $2.53B in annual revenue (up from $1.53B in FY2024, +65.3% YoY) and $265.2K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.32B revenue, $272.5K net income) through FY2025, CHE scaled operating cash flow to $388.3M and free cash flow to $325.5M, backed by $1.54B in total assets against $251.5M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (A- • RQD 83/100): Strong cash generator (32.5% gross margin)—profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 17/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $365.21 – $562.24 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh current valuation and 18.5x EV/EBITDA against 13.4% operating margins and a 1.08x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— The only sector context provided is that CHE is classified under Health Care and Medical/Nursing Services.

  • Key Question #1: Can CHE sustain or expand its 13.4% operating margin and 23.4% ROIC against Medical/Nursing Services peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $2.53B and free cash flow of $325.5M, how will capital allocation balance growth reinvestment against $251.5M in total debt?
  • Key Question #3: How sensitive is CHE's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.08x)?

CHE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Chemed Corp (CHE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CHE Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CHE Bull vs. Bear Conversation Board — What's Your Call at $534.72?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CHE 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CHE:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $668.40 (+25.0%)
📌 Pinned Debate

Per the Roarable RQD rating, a 23.4% ROIC and 18/20 forensic balance-sheet score signal a cash-generative, low-leverage business.

Don't sleep on CHE's setup in Health Care. Per the Roarable RQD rating, a 23.4% ROIC and 18/20 forensic balance-sheet score signal a cash-generative, low-leverage business.. Beta of 1.08 means it moves fast when momentum turns, and the 5-pillar RQD gauge (83/100) backs up the fundamental quality.

CapAlloc_Nerd 🐂 BULL

@CreditSpread_Watch Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Nursing Services. If gross margin (32.5%) holds, EPS grows into the multiple faster than bears think.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $411.73 (-23.0%)
Spot @ $534.72

At EV/EBITDA of 18.5 with the stock near its 52-week high of $562.24, valuation leaves limited margin for error.

Fading this rally in CHE at $534.72. At EV/EBITDA of 18.5 with the stock near its 52-week high of $562.24, valuation leaves limited margin for error.. With a beta of 1.08 and the stock sitting at $534.72 (52-wk range $365.21–$562.24), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%